Objective Research objectives ant content Our recent finding indicate that CD40-CD40L represent an important NK cytotoxicity activation pathway. One of the objectives of this proposal is to investigate the possibility that CD40 can be expressed on tumor cells and whether it can be recognized by autologous NK cells. The second objective is to generate new monoclonal antibodies panel to NK cells (NKmAbs) able to tune NK cell programs not only related to cytotoxicity function but also cytokine production. Training content (objective. benefit and expected impact) The benefit for the proponent is to improve capability to develop new monoclonal antibodies, and strenghted his knowledge in tumor immunology. The expected impact is to make available, a complete reagent panel able to give selective tuning of NK function, moreover the importance of the CD40-CD40L activatory pathway will be determined in a tumor cell system. Links with industry / industrial relevance (22) The project will be carried out in collaboration with the MABTECH AB (Stockholm), the specific NK mAbs can be patented. Fields of science medical and health sciencesbasic medicineimmunology Programme(s) FP4-TMR - Specific research and technological development programme in the field of the training and mobility of researchers, 1994-1998 Topic(s) 0302 - Post-doctoral research training grants TL07 - Immunology and Cancer Call for proposal Data not available Funding Scheme RGI - Research grants (individual fellowships) Coordinator KAROLINSKA INSTITUTE Address 13,nobels väg 16 171 77 Stockholm Sweden See on map EU contribution € 0,00 Participants (1) Sort alphabetically Sort by EU Contribution Expand all Collapse all Not available Italy EU contribution € 0,00 Address See on map
